Top 5 Probiotic Strains to Reduce Chronic Inflammation
Chronic inflammation has become an important area of research in nutrition, microbiome science and functional health. Unlike the short-lived inflammatory response that helps the body respond to injury or infection, chronic low-grade inflammation can persist for long periods and is associated with a wide range of physiological disturbances.
However, an important distinction is necessary: not all probiotics have the same biological effects, and probiotic activity is generally strain-specific. A statement about Lactobacillus as a genus should not automatically be interpreted as evidence for every Lactobacillus strain. Likewise, evidence for one Bifidobacterium strain cannot simply be transferred to another.
Clinical meta-analyses provide some support for these concepts. A meta-analysis of 42 randomized clinical trials involving more than 2,200 participants reported reductions in several inflammatory biomarkers following probiotic supplementation, including hs-CRP, TNF-α and IL-6, although effects differed between biomarkers and studies. [1] More recent umbrella-level evidence has similarly reported reductions in CRP, TNF-α and IL-6, while also emphasizing substantial heterogeneity between trials. [2]
A 2023 systematic review and meta-analysis focusing on intestinal barrier function found that probiotics improved several measures associated with barrier integrity and were also associated with reductions in CRP, TNF-α and IL-6. [3]
These findings do not mean that probiotics should be considered anti-inflammatory medicines. Rather, they indicate that certain probiotic interventions may influence biological pathways relevant to inflammation.
This article examines five probiotic strains or strain groups with particularly relevant scientific evidence
The selection reflects a combination of strain-specific research, human studies, mechanistic evidence and relevance to gut-barrier and immune-function research.
What Is Chronic Inflammation?
Inflammation is a normal biological defense mechanism. It helps the body respond to infection, tissue injury and other challenges. Acute inflammation is generally temporary and resolves after the tri ering stimulus has been controlled.
Chronic inflammation is different. It involves persistent or repeatedly activated inflammatory pathways and may occur at a relatively low level for extended periods. Chronic inflammatory signaling can involve cytokines, immune cells, oxidative stress, epithelial barrier changes and interactions between host tissues and microorganisms.
The gut microbiome contains bacteria capable of producing metabolites that interact with host physiology.
These include:
short-chain fatty acids;
indole-derived metabolites;
bile-acid derivatives;
microbial cell-wall components;
polysaccharides;
organic acids;
other bioactive microbial compounds.
Short-chain fatty acids such as acetate, propionate and butyrate are particularly important areas of research.
A review specifically examining chronic low-grade inflammation noted that lactobacilli and bifidobacteria may influence gut permeability and LPS-dependent inflammatory pathways. [4]
However, the human microbiome is complex, and probiotic supplementation does not simply replace an entire microbial ecosystem.
The goal of modern probiotic science is increasingly moving toward specific strain–host interactions, rather than the simplistic concept of adding more “good bacteria.”
How Probiotic Strains May Influence Inflammatory Pathways
The potential relationship between probiotics and inflammation involves several interconnected mechanisms.
Gut-barrier support
The intestinal epithelial barrier regulates what moves from the intestinal lumen into systemic circulation.
Tight junctions between epithelial cells help control permeability.
Experimental and clinical research suggests that certain probiotics may influence:
tight-junction proteins;
epithelial integrity;
mucus interactions;
intestinal permeability;
microbial translocation;
endotoxin exposure.
A 2023 systematic review and meta-analysis of 26 randomized trials involving 1,891 participants found improvements in several measures of intestinal barrier function following probiotic intervention. The analysis also reported reductions in inflammatory factors including CRP, TNF-α and IL-6. [3]
This is important because barrier function may represent one link between the intestinal microbiome and systemic inflammatory signaling.
Immune modulation
Probiotics interact with immune cells through microbial-associated molecular patterns and host pattern-recognition receptors.
These interactions can influence pathways involving:
Toll-like receptors;
NF-κB;
dendritic cells;
macrophages;
regulatory T cells;
cytokine production.
The objective is not necessarily to “turn off” immunity.
A healthy immune system requires an appropriate response to pathogens and tissue damage. Therefore, probiotic research often focuses on immune modulation rather than generalized immune suppression.
Cytokine signaling
Inflammatory research commonly examines biomarkers such as:
C-reactive protein;
TNF-α;
IL-6;
IL-1β;
IL-8;
IL-10;
IL-12;
IFN-γ.
The evidence is not uniform across all biomarkers.
For example, one meta-analysis found significant reductions in hs-CRP, TNF-α and IL-6 but no significant effects on several other cytokines. [1]
This illustrates why probiotic claims should be based on the specific strain, study population, dose, duration and outcome measure.
Microbial metabolites
Some probiotic effects may occur indirectly by influencing the broader microbial ecosystem.
Microbial metabolites can affect:
epithelial metabolism;
immune signaling;
intestinal pH;
microbial competition;
host energy metabolism;
gut–brain communication.
The interaction is therefore better represented as:
Probiotic strain → microbial ecosystem → metabolites/signaling → intestinal barrier → immune response
rather than:
Probiotic strain → direct reduction of inflammation
This distinction is particularly important for scientifically responsible product development.
Top 5 Probiotic Strains for Chronic Inflammation
1. Lactiplantibacillus plantarum

Lactiplantibacillus plantarum, historically referred to as Lactobacillus plantarum, is one of the most interesting strains for research involving the gut, immune function and inflammatory biomarkers.
The strain has been studied in human populations, including individuals with cardiovascular risk and gastrointestinal considerations.
One notable randomized human study examined Lactiplantibacillus plantarum in men with stable coronary artery disease. Participants consumed the probiotic for six weeks. The study reported improved flow-mediated dilation and reductions in circulating IL-8 and IL-12, together with changes in selected microbial metabolites including propionate. [5]
The importance of this study is not that Lactiplantibacillus plantarum should be marketed as a cardiovascular treatment.
Rather, it provides an example of how a specific probiotic strain may interact with vascular physiology, microbial metabolites and inflammatory signaling.
Potential role in inflammatory biology
Research surrounding Lactiplantibacillus plantarum points toward several areas:
intestinal microbial interaction;
epithelial and barrier support;
immune modulation;
microbial metabolite production;
systemic inflammatory biomarkers;
host–microbiome communication.
A broader meta-analysis of randomized clinical trials involving Lactiplantibacillus plantarum strains found effects on several immune parameters, including reductions in TNF-α and increases in IL-10. However, the analysis included multiple Lactiplantibacillus plantarum strains, so these findings should not automatically be attributed exclusively to Lactiplantibacillus plantarum. [6]
This distinction is critical in formulation science.
Application areas
Lactiplantibacillus plantarum may be considered in formulations targeting:
gut health;
microbiome support;
healthy aging;
metabolic wellness;
cardiovascular wellness;
functional nutrition;
stress-related gut support;
multi-strain microbiome formulations.
For B2B manufacturers, the strain may be particularly interesting where a formulation requires a well-characterized Lactobacillus-derived component with human research relating to inflammatory and vascular biomarkers.
Formulation considerations
Lactiplantibacillus plantarum is a living microorganism, so formulation development should consider:
viable count at end of shelf life;
moisture exposure;
oxygen sensitivity;
storage temperature;
matrix compatibility;
packaging barrier properties;
gastric survival;
regulatory requirements;
strain authentication.
The presence of a probiotic strain at the beginning of shelf life is not sufficient. Manufacturers should establish that the intended viable count remains available throughout the declared shelf life.
2. Lacticaseibacillus rhamnosus

Lacticaseibacillus rhamnosus is among the most extensively studied probiotic strains and has a substantial literature covering gastrointestinal function, epithelial interactions and immune modulation.
Its relevance to chronic inflammation lies particularly in its interaction with the intestinal barrier and host immune system.
This provides a mechanistic connection between: [6D]
A randomized intervention study in healthy adults investigated Lacticaseibacillus rhamnosus -associated changes in serum lipidomic profiles alongside inflammatory variables including CRP, TNF-α and IL-6. [7]
The results demonstrate why Lacticaseibacillus rhamnosus is scientifically interesting but also why probiotic evidence should not be overstated.
Not every study shows significant changes in every inflammatory marker.
For example, a randomized controlled trial in older care-home residents using Lacticaseibacillus rhamnosus combined with Bifidobacterium animalis subsp. lactis found limited effects on a broad range of immune and inflammatory biomarkers. [8]
This negative or neutral result is valuable.
It shows that even highly studied strains do not produce uniform effects across every population.
Potential applications
Lacticaseibacillus rhamnosus can be considered in formulations involving:
gastrointestinal wellness;
intestinal barrier support;
immune health;
digestive health;
recovery-oriented nutrition;
multi-strain probiotic blends.
Its extensive research history may also make it useful for B2B customers seeking strains with substantial documentation.
Key formulation lesson
The Lacticaseibacillus rhamnosus example illustrates a major principle:
A highly documented strain is not necessarily universally effective for every inflammatory outcome.
The relevant question is:
Which strain, in which population, at what dose, for what duration, and against which defined outcome?
This is the level at which modern probiotic formulation should operate.
3. Bifidobacterium longum

A particularly interesting immune-modulating strain
Bifidobacterium longum is one of the most scientifically interesting Bifidobacterium strains in the context of immune regulation.
Its importance extends beyond simple changes in bacterial abundance.
Research has investigated how specific molecular structures on the surface of the strain interact with immune cells.
One particularly interesting feature is its surface-associated exopolysaccharide.
Experimental research demonstrated that this structure plays an important role in dampening pro-inflammatory responses. The study found that Bifidobacterium longum induced relatively low cytokine secretion from human dendritic cells, while an exopolysaccharide-deficient derivative produced substantially greater inflammatory signaling. [9]
This provides an excellent example of why strain-level identity matters.
Two organisms may belong to the same species while possessing different molecular characteristics and biological effects.
Regulatory immune signaling
Research into Bifidobacterium longum has connected the strain with pathways involving:
dendritic cells;
T-regulatory responses;
IL-10;
TGF-β;
Th17-related signaling;
mucosal immune regulation.
A clinical perspective on microbiome manipulation described Bifidobacterium longum as an example of probiotic interaction with intestinal immune pathways leading toward regulatory immune responses. [10]
Gastrointestinal applications
Bifidobacterium longum has also been studied extensively in functional gastrointestinal conditions.
Clinical studies have reported improvements in IBS-related outcomes in selected populations. [11]
Bifidobacterium longum may be relevant to:
gut-health products;
digestive wellness;
microbiome-support formulations;
immune-support concepts;
gut–brain-axis formulations;
multi-strain products;
personalized nutrition concepts.
Why strain specificity matters
The Bifidobacterium longum example is perhaps one of the strongest arguments against using species-level claims.
For professional B2B formulation, the latter is considerably more meaningful.
4. Bifidobacterium animalis subsp. lactis

Bifidobacterium animalis subsp. lactis is another extensively documented probiotic strain. It has a long history of research involving gastrointestinal function and immune interactions.
A human crossover study involving 30 healthy adults examined B. animalis subsp. lactis delivered in different food matrices and found evidence of interaction with peripheral myeloid cells through Toll-like receptor 2.
In one delivery format, B. animalis subsp. lactis consumption was associated with reduced TLR-2 expression and lower TNF-α secretion from stimulated peripheral blood mononuclear cells. [12]
This study is particularly interesting because it demonstrates that the delivery matrix itself may influence probiotic effects.
That is highly relevant to product development.
The same strain may behave differently depending on whether it is delivered through:
capsules;
fermented dairy;
powder;
sachets;
functional beverages;
other food matrices.
Documentation and stability
Bifidobacterium animalis subsp. lactis is also notable because of its extensive scientific documentation.
A review of B. animalis subsp. lactis described evidence relating to:
gastric and bile tolerance;
mucus interaction;
pathogen inhibition;
intestinal barrier effects;
immune interactions;
gastrointestinal applications.[13]
For manufacturers, this makes B. animalis subsp. lactis an interesting candidate when documentation, strain identity and manufacturing robustness are important selection criteria.
Potential applications can be considered for:
daily gut-health products;
digestive wellness;
immune-support formulations;
functional foods;
fermented dairy products;
powdered probiotic blends;
capsules;
sachets.
Important limitation
Not every clinical trial produces significant changes in inflammatory biomarkers.
For example, a randomized controlled trial in older adults receiving L plus found limited changes across a broad range of inflammatory and immune measurements. [8]
This reinforces the principle that probiotic efficacy depends on the complete intervention design.
5. Lactobacillus casei Shirota

Lactobacillus casei Shirota, often abbreviated LcS, is another extensively researched strain. It has been used for decades in fermented milk and probiotic food products and has been investigated in relation to intestinal microbiota, immune responses and inflammatory physiology.
An early human study found that consumption of milk fermented with Lactobacillus casei Shirota increased fecal Lactobacillus counts and was associated with an increase in Bifidobacterium counts. [14]
Human research has examined Lactobacillus casei Shirota in relation to immune cell activation and cytokine production. Mechanistic work has also identified strain-associated cell-wall polysaccharides that can influence macrophage cytokine responses. [15]
Animal research has explored pathways involving NF-κB, bile-acid metabolism and inflammatory signaling. [16]
However, animal and mechanistic evidence should not be presented as proof of equivalent effects in humans.
Human inflammatory research
A randomized clinical study in people with metabolic syndrome investigated Lactobacillus casei Shirota supplementation for 12 weeks and assessed insulin sensitivity, endothelial function and inflammatory parameters. [17]
Other clinical research has investigated Lactobacillus casei Shirota in osteoarthritis, with one large randomized controlled trial reporting lower hs-CRP alongside improvements in clinical outcome measures. [18]
Again, these findings should be interpreted within the specific study population rather than generalized to all inflammatory conditions.
Potential applications
Lactobacillus casei Shirota may be relevant to:
fermented functional foods;
daily probiotic beverages;
gut-health formulations;
immune wellness products;
metabolic wellness concepts;
multi-strain probiotic formulations.
What Do Meta-Analyses Tell Us?
Individual strain studies are important, but systematic reviews and meta-analyses provide a broader view.
A 2020 meta-analysis included 42 randomized clinical trials and found significant reductions in several inflammatory biomarkers, including hs-CRP, TNF-α, IL-6 and IL-12, together with an increase in IL-10. [1]
A 2023 umbrella meta-analysis of randomized controlled trials similarly reported reductions in CRP, TNF-α and IL-6 following probiotic supplementation. [2]
A more recent systematic review and meta-analysis focused on non-communicable diseases and reported significant reductions in CRP and TNF-α, as well as markers of oxidative stress, while finding inconsistent effects on IL-6 and other outcomes. [19]
Another 2026 systematic review and meta-analysis of randomized placebo-controlled trials examined oxidative/nitrosative stress and inflammation in non-communicable diseases. It reported beneficial effects on some markers, including hsCRP, glutathione and malondialdehyde, but no consistent effect across all inflammatory outcomes. [20]
Why Strain Selection Matters More Than the Species Name
One of the most important principles in probiotic formulation is that species does not equal strain.
A strain may possess unique:
Surface proteins
Exopolysaccharides
Adhesion characteristics
Metabolic pathways
Bile tolerance
Acid tolerance
Immune interactions
Metabolite-production capacity.
Therefore, a scientifically designed probiotic product should document the identity of the actual strain used.
Probiotic Strains and the Intestinal Barrier
The intestinal barrier deserves special attention in chronic-inflammation research.
The barrier consists of:
Mucus
Epithelial cells
Tight junctions
Immune components
Resident microorganisms
Microbial metabolites.
Barrier disruption may increase exposure to microbial molecules and contribute to immune activation.
The 2023 meta-analysis of 26 randomized controlled trials provides evidence that probiotic interventions can improve several markers associated with intestinal barrier function. [3]
This provides a potential framework for understanding why some probiotic interventions may influence inflammatory biomarkers.
The proposed sequence is[11D]
This is a biological hypothesis supported to varying degrees by experimental and clinical evidence—not a guarantee of a particular clinical outcome.
Probiotics, LPS and Low-Grade Inflammation
Probiotic research has therefore examined whether modulation of gut microbiota and barrier function could influence circulating endotoxin or LPS-associated pathways.
The 2023 barrier-function meta-analysis reported improvements in endotoxin and LPS-related measures in probiotic groups. [3]
However, LPS is only one component of a much larger inflammatory network.
It would therefore be scientifically inappropriate to describe probiotics simply as “LPS blockers.”
Their potential biological effects are considerably broader and may involve multiple microbial, epithelial and immune pathways.
Potential Applications of Probiotic Strains for Chronic Inflammation
The scientific evidence creates several potential areas for formulation development.
Gut-health products
This is perhaps the most direct application.
Metabolic wellness products
Potential formulation concepts include:
metabolic wellness;
healthy glucose metabolism;
healthy lipid metabolism;
weight-management support;
healthy aging.
Functional foods and beverages
Several strains are suitable for functional-food applications, depending on stability and processing requirements.
B2B Formulation Considerations
For nutraceutical and functional-food manufacturers, choosing a probiotic strain is only one part of the development process.
Strain authentication
The identity of the strain should be confirmed using appropriate analytical methods.
Viability
The declared CFU should reflect the intended potency at the relevant stage of product life, particularly at end of shelf life where regulations require or market practice expects such specification.
Regulatory compliance
A probiotic formulation intended for the European Union, United States, United Kingdom, GCC, India or another market must be evaluated against the applicable food, supplement and health-claim requirements.
Scientific evidence alone does not automatically authorize a health claim.
Single-Strain vs Multi-Strain Formulations
The five strains discussed in this article can be considered individually or as components of multi-strain formulations.
A multi-strain approach may be attractive because different strains can potentially provide complementary functional characteristics.
For example:
Lactiplantibacillus plantarum may contribute to microbial and metabolic interactions.
Lacticaseibacillus rhamnosus may contribute to barrier and immune research.
Bifidobacterium longum provides particularly interesting strain-specific immune-modulation research.
Bifidobacterium animalis subsp. lactis has extensive documentation around gastrointestinal and immune interactions.
Lactobacillus casei Shirota has a long history of research in fermented-food applications and host–microbiome interactions.
However, combining strains should not be based simply on the assumption that “more strains mean more benefits.”
Potential interactions between strains, dose, manufacturing conditions and product matrix must be evaluated.
Where Does Bacillus coagulans Fit?
chronic-inflammation formulation concept also includes Bacillus coagulans. [21]
Bacillus-based probiotics are particularly interesting from a formulation perspective because spore-forming organisms can offer advantages in terms of processing and stability.
This can be useful for:
powders;
sachets;
tablets;
shelf-stable formulations;
products exposed to challenging manufacturing conditions.
However, the evidence profile for Bacillus strains differs from that of the five strains discussed in detail above.
Importantly, “Bacillus coagulans” itself is not a single homogeneous biological entity. Strain identity remains important.
Therefore, manufacturers should evaluate the specific strain rather than extrapolating evidence from one Bacillus strain to another.
Emerging Next-Generation Microbes
The SwissMedicare chronic-inflammation page also identifies Faecalibacterium prausnitzii and Akkermansia muciniphila as next-generation or emerging microbiome candidates. [21]
These organisms are scientifically important but should not automatically be treated as equivalent to established conventional probiotics.
Akkermansia muciniphila, for example, has attracted considerable research interest because of its association with:
intestinal mucus ecology;
metabolic health;
epithelial barrier function;
microbial-host signaling.
However, formulation strategies involving emerging microbes require careful consideration of:
viability;
cultivation;
storage;
regulatory status;
manufacturing reproducibility;
clinical evidence;
strain specificity.
This is one reason the future of probiotic formulation is likely to include a spectrum of live microorganisms, defined microbial components and postbiotic preparations rather than one universal probiotic model.
Probiotics Are Not a Replacement for Medical Treatment
Chronic inflammation can be associated with many different biological and clinical conditions.
A probiotic should not be positioned as a replacement for:
medical diagnosis;
prescribed treatment;
nutritional therapy;
physical activity;
sleep management;
smoking cessation;
appropriate management of metabolic risk factors.
A person with persistent symptoms or a diagnosed inflammatory condition should receive appropriate medical assessment.
For product communication, phrases such as:
“supports healthy inflammatory balance”
or
“supports gut-barrier and microbiome health”
may be more scientifically appropriate than disease-treatment statements, subject to the regulations of the target market.
Claims such as “treats arthritis,” “cures IBD,” or “prevents diabetes” require a much higher level of clinical and regulatory substantiation and may be prohibited for foods or dietary supplements in many jurisdictions.
What the Current Evidence Really Supports
The evidence can be summarized in five levels.
Stronger evidence
There is substantial evidence that certain probiotic interventions can influence some gastrointestinal outcomes and selected inflammatory biomarkers.
Moderate evidence
There is growing evidence for effects on intestinal barrier-related measures and immune signaling.
Strain-specific evidence
Some strains have distinctive mechanistic and human data, including Lactiplantibacillus plantarum and Bifidobacterium longum.
Inconsistent evidence
Not every probiotic produces the same effects, and not every inflammatory biomarker responds.
Important research gap
Large, well-controlled, strain-specific clinical trials with standardized outcomes are still needed.
How to Select a Probiotic Strain for an Anti-Inflammatory-Oriented Formulation
A practical B2B selection framework can include:
Step 1: Define the intended benefit
gut health?
immune wellness?
metabolic wellness?
healthy aging?
functional nutrition?
Step 2: Identify the relevant biological pathway
intestinal barrier;
cytokine modulation;
microbial metabolites;
oxidative stress;
LPS/endotoxin exposure.
Step 3: Select the strain
Use the documented strain identity.
Step 4: Review human evidence
Prioritize
Randomized controlled trials
Systematic reviews
Meta-analyses
Mechanistic studies
Observational research.
Step 5: Evaluate formulation stability
Determine whether the strain can survive:
manufacturing;
storage;
transportation;
gastrointestinal conditions.
Step 6: Determine the appropriate dose
Dose should be based on available evidence for the actual strain and intended application rather than a generic assumption that a higher CFU count is always better.
Step 7: Build regulatory documentation
The final product should have:
strain identity;
specifications;
microbiological testing;
stability data;
certificates of analysis;
safety documentation;
regulatory assessment;
appropriate claim substantiation.
A Science-Based View of “Anti-Inflammatory Probiotics”
The term “anti-inflammatory probiotic” is useful for describing an area of research, but it can be misleading if interpreted too broadly.
Probiotics do not necessarily act like conventional anti-inflammatory drugs.
Their potential biological effects may be indirect and distributed across the gut ecosystem.
Future Directions
The next generation of probiotic research is likely to become increasingly precise.
Future studies may focus on
strain-level genomics
microbiome profiling
metabolomics
immune phenotyping
personalized nutrition
responder/non-responder identification
defined microbial consortia
synbiotics
postbiotics
next-generation probiotics
Related Reading from Swiss Medicare
Developing an inflammation-focused formulation? Contact our team for strain specifications, documentation and a bulk quote.
Frequently Asked Questions (FAQ)
1. What are the best probiotic strains for chronic inflammation?
There is no single probiotic strain that can be considered universally “best” for chronic inflammation. Research has investigated several strains, including Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus, Bifidobacterium longum, Bifidobacterium animalis subsp. lactis and Lactobacillus casei Shirota. Evidence varies according to the strain, population, dosage, duration and inflammatory biomarker being studied.
2. Can probiotics reduce chronic inflammation?
Clinical research suggests that selected probiotic interventions may influence some inflammatory biomarkers, including C-reactive protein (CRP), TNF-α and IL-6. A systematic review and meta-analysis of randomized trials also reported improvements in selected measures of intestinal barrier function. However, results are heterogeneous, and probiotics should not be considered a universal treatment for chronic inflammatory conditions.
3. Which probiotic strains have been studied for inflammatory biomarkers?
Several strains have been investigated in human studies, including Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus, Bifidobacterium longum, Bifidobacterium animalis and Lactobacillus casei Shirota. The strength and type of evidence differ between strains.
4. How may probiotics influence inflammation?
Potential mechanisms include interaction with the intestinal epithelial barrier, modulation of microbial metabolites, interaction with immune cells and changes in cytokine signaling. Some studies have also investigated whether probiotics can influence endotoxin or lipopolysaccharide-related pathways.
5. Can probiotics improve gut-barrier function?
Some clinical evidence suggests that selected probiotic interventions can improve specific measures of intestinal barrier function. A systematic review and meta-analysis of randomized trials reported improvements in transepithelial resistance, serum zonulin, endotoxin and LPS, although not every measure of permeability improved consistently. [1]
6. Is Lactiplantibacillus plantarum studied for inflammation?
Yes. Lactiplantibacillus plantarum has been investigated in human studies involving inflammatory biomarkers, vascular function and microbial metabolites. Broader meta-analyses of Lactiplantibacillus plantarum strains have also reported effects on selected immune parameters.
7. Is Lactobacillus rhamnosus an anti-inflammatory probiotic?
Lacticaseibacillus rhamnosus, commonly known as L, has extensive research involving intestinal barrier function, gastrointestinal health and immune interactions. It may influence biological pathways relevant to inflammation, but it should not be described as a medicine or as a treatment for chronic inflammatory disease.
8. What is special about Bifidobacterium longum ?
Bifidobacterium longum has particularly interesting strain-specific research involving immune regulation. Experimental studies have investigated its surface-associated exopolysaccharide and interactions with dendritic cells and regulatory immune pathways. [2]
9. Is Lactobacillus casei Shirota studied for inflammation?
Yes. Lactobacillus casei Shirota has been investigated in human and experimental studies involving the intestinal microbiota, immune responses and inflammatory biomarkers. Evidence should nevertheless be interpreted according to the specific population and outcome studied.
10. Are probiotics the same as anti-inflammatory medicines?
No. Probiotics and pharmaceutical anti-inflammatory medicines have fundamentally different mechanisms and evidence bases. Probiotics are living microorganisms that may influence the gut microbiome, intestinal barrier and host signaling. They should not be presented as replacements for medically indicated treatment.
11. Does a higher CFU count mean a probiotic will work better?
Not necessarily. Probiotic effects are strain-specific and dose-dependent, but a higher CFU count does not automatically mean greater biological effectiveness. The scientifically relevant dose should be supported by evidence for the specific strain and intended application.
12. Are multi-strain probiotics better than single-strain probiotics?
Not automatically. Multi-strain formulations may provide complementary characteristics, but combining strains does not guarantee additive or synergistic effects. Compatibility, dosage, stability, manufacturing conditions and evidence for the actual combination should be evaluated.
13. Why is strain identification important in probiotic products?
Different strains belonging to the same species can have different genomic characteristics, surface structures, metabolic capabilities and host interactions. Therefore, scientific evidence for one strain should not automatically be transferred to another strain of the same species.
14. Can probiotics affect CRP, TNF-α or IL-6?
15. Can probiotics reduce intestinal permeability?
Some probiotic interventions have improved selected measurements associated with intestinal barrier function. However, different permeability tests do not always produce the same results, and evidence remains dependent on the population and probiotic intervention.
16. What should manufacturers consider when developing a probiotic for inflammation-related wellness?
Manufacturers should consider strain identity, clinical evidence, viable count, stability, formulation matrix, shelf life, packaging, manufacturing conditions, safety documentation and regulatory requirements. Claims should be based on evidence for the actual strain and product rather than generalized probiotic research.
17. Can probiotics be used in functional foods and beverages?
Yes. Depending on strain characteristics and regulatory requirements, probiotic strains can be incorporated into products such as capsules, powders, sachets, fermented foods and functional beverages. Stability and viable-count requirements need to be evaluated for the finished product.
18. What is the relationship between probiotics and the gut microbiome?
Probiotics may interact with resident microorganisms, intestinal epithelial cells and host immune pathways. They may also influence microbial metabolites and the broader microbial environment. However, probiotic supplementation does not necessarily permanently colonize the intestine.
Scientific References:
[1] Zheng Y, Zhang Z, Tang P, et al. Probiotics fortify intestinal barrier function: a systematic review and meta-analysis of randomized trials. Frontiers in Immunology. 2023;14:1143548.PMID: 37168869 | PMCID: PMC10165082 PubMedPubMed Central [2] Schiavi E, Gleinser M, Miani M, et al. The surface-associated exopolysaccharide of Bifidobacterium longum plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses. Applied and Environmental Microbiology. 2016.PMID: 27736791 | PMCID: PMC5118929 PubMed
[3] Milajerdi A, Mousavi SM, Saneei P, et al. The effect of probiotics on inflammatory biomarkers: a meta-analysis of randomized clinical trials. European Journal of Nutrition. 2020.PMID: 30854594PubMed
[4] Hutchinson AN, Tingö L, Brummer RJ. The potential effects of probiotics and ω-3 fatty acids on chronic low-grade inflammation. Nutrients. 2020.PMID: 32796608 | PMCID: PMC7468753 PubMed
[5] Malik M, et al. Lactobacillus plantarum supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable coronary artery disease. Circulation Research.PMID: 30355158 | PMCID: PMC6205737 PubMed
[6] Wang Y, et al. Meta-analysis: randomized trials of Lactobacillus plantarum on immune regulation over the last decades.PMID: 33828554 PubMed
[7] de Vos WM, et al. Strain-specific probiotic research and host–microbe interactions.
For the broader evidence base, see the PubMed-indexed literature on Lacticaseibacillus rhamnosus .PubMed search — Lacticaseibacillus rhamnosus inflammation
[8] Castro-Herrera VM, et al. Combination of the probiotics Lacticaseibacillus rhamnosus and Bifidobacterium animalis subsp. lactis has limited effect on biomarkers of immunity and inflammation in older people. Frontiers in Immunology. 2021.PMID: 33746986 PubMed
[9] The science behind the probiotic strain Bifidobacterium animalis subsp. lactis.
PMID: 27682233 PubMed
[10] Consumption of Bifidobacterium animalis subsp. lactis in yogurt and effects on TLR-2 expression and inflammatory cytokine secretion. PMID: 26621631PubMed
[11] Spanhaak S, Havenaar R, Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on intestinal microflora and immune parameters in humans.PMID: 9881885PubMed
[12] Suppressive effect on activation of macrophages by Lactobacillus casei strain Shirota genes determining synthesis of cell wall-associated polysaccharides.PMID: 18552190 | PMCID: PMC2519339 PubMed PMC
[13] Lactobacillus casei strain Shirota and intestinal/immune effects.
Europe PMC search
[14] Tripolt NJ, et al. Effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, β-cell function, endothelial function and inflammation in subjects with metabolic syndrome. PMID: 23164226 PubMed
[15] The effect of probiotic Lactobacillus casei Shirota on knee osteoarthritis: randomized double-blind placebo-controlled clinical trial.PMID: 28726510PubMed
[16] Bifidobacterium and intestinal epithelial tight-junction barrier: current knowledge and perspectives.PMID: 38076401 | PMCID: PMC10700415 PubMed PMC
[17] Pharmabiotic manipulation of the microbiota in gastrointestinal disorders: a clinical perspective.PMID: 29684976PubMed
[18] Sabaté JM, Iglicki F. Effect of Bifidobacterium longum on disease severity and quality of life in patients with irritable bowel syndrome.PMID: 35317278 | PMCID: PMC8891724 PubMed PMC
[19] The health benefits of probiotic Lactiplantibacillus plantarum: a systematic review and meta-analysis. 2024.PMID: 38816672 | PMCID: PMC12532744 PubMedPMC
[20] Strain-specific systematic review with meta-analysis of probiotics efficacy in IBS.
PMID: 41682832 This newer analysis specifically identifies evidence for Bifidobacterium longum, Lacticaseibacillus rhamnosus and Lactiplantibacillus plantarum among other strains.
PubMed


Comments